191 related articles for article (PubMed ID: 17217418)
1. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.
Tkac I; Dubinsky JM; Keene CD; Gruetter R; Low WC
J Neurochem; 2007 Mar; 100(5):1397-406. PubMed ID: 17217418
[TBL] [Abstract][Full Text] [Related]
2. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
3. Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy.
Tkác I; Keene CD; Pfeuffer J; Low WC; Gruetter R
J Neurosci Res; 2001 Dec; 66(5):891-8. PubMed ID: 11746416
[TBL] [Abstract][Full Text] [Related]
4. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
[TBL] [Abstract][Full Text] [Related]
5. Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model.
Choo YS; Mao Z; Johnson GV; Lesort M
Neurosci Lett; 2005 Sep; 386(1):63-8. PubMed ID: 15993538
[TBL] [Abstract][Full Text] [Related]
6. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy.
Tsang TM; Woodman B; McLoughlin GA; Griffin JL; Tabrizi SJ; Bates GP; Holmes E
J Proteome Res; 2006 Mar; 5(3):483-92. PubMed ID: 16512662
[TBL] [Abstract][Full Text] [Related]
7. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice.
van Dellen A; Welch J; Dixon RM; Cordery P; York D; Styles P; Blakemore C; Hannan AJ
Neuroreport; 2000 Nov; 11(17):3751-7. PubMed ID: 11117485
[TBL] [Abstract][Full Text] [Related]
8. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
[TBL] [Abstract][Full Text] [Related]
9. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
[TBL] [Abstract][Full Text] [Related]
10. Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.
Herbst EA; Holloway GP
Neuroscience; 2015 Sep; 303():515-23. PubMed ID: 26186895
[TBL] [Abstract][Full Text] [Related]
11. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.
Rebec GV; Conroy SK; Barton SJ
Neuroscience; 2006; 137(1):327-36. PubMed ID: 16257492
[TBL] [Abstract][Full Text] [Related]
12. Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.
Zacharoff L; Tkac I; Song Q; Tang C; Bolan PJ; Mangia S; Henry PG; Li T; Dubinsky JM
J Cereb Blood Flow Metab; 2012 Mar; 32(3):502-14. PubMed ID: 22044866
[TBL] [Abstract][Full Text] [Related]
13. Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress.
Lou S; Lepak VC; Eberly LE; Roth B; Cui W; Zhu XH; Öz G; Dubinsky JM
Hum Mol Genet; 2016 Jul; 25(13):2813-2826. PubMed ID: 27193167
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
Petr GT; Schultheis LA; Hussey KC; Sun Y; Dubinsky JM; Aoki C; Rosenberg PA
Eur J Neurosci; 2013 Aug; 38(3):2477-90. PubMed ID: 23586612
[TBL] [Abstract][Full Text] [Related]
15. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
[TBL] [Abstract][Full Text] [Related]
17. Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice.
Sorolla MA; Rodríguez-Colman MJ; Vall-Llaura N; Vived C; Fernández-Nogales M; Lucas JJ; Ferrer I; Cabiscol E
Metab Brain Dis; 2016 Jun; 31(3):579-86. PubMed ID: 26666246
[TBL] [Abstract][Full Text] [Related]
18. Metabolic signatures of Huntington's disease (HD): (1)H NMR analysis of the polar metabolome in post-mortem human brain.
Graham SF; Kumar PK; Bjorndahl T; Han B; Yilmaz A; Sherman E; Bahado-Singh RO; Wishart D; Mann D; Green BD
Biochim Biophys Acta; 2016 Sep; 1862(9):1675-84. PubMed ID: 27288730
[TBL] [Abstract][Full Text] [Related]
19. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease.
Simmons DA; Casale M; Alcon B; Pham N; Narayan N; Lynch G
Glia; 2007 Aug; 55(10):1074-84. PubMed ID: 17551926
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
